Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

13.04 -4.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.01

Max

13.19

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	312K -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+141.78% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-161M 1.2B
Vorige openingsprijs	17.44
Vorige sluitingsprijs	13.04

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 jul 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Saturday's session, building on Friday's gains. The price movement aligns with Ethereum's upward trend.

25 jul 2026, 23:42 UTC

Personal Income MoM Data Release on July 30, 2026, Forecasts Modest Growth Amid Ongoing Market Volatility and Geopolitical Concerns.

25 jul 2026, 23:42 UTC

U.S. Personal Spending Expected to Rise 0.4% in June Amid Inflation and Geopolitical Tensions Impacting Consumer Behavior

25 jul 2026, 23:42 UTC

Market Awaits Key PCE Price Index Data on July 30, 2026, Amid Rising Inflation Concerns and Potential Impact on Federal Reserve Policy.

25 jul 2026, 23:42 UTC

South Korea's exports surge 70.9% in June, with August release expected to reveal continued growth amid cautious investor sentiment due to inflation and geopolitical tensions.

25 jul 2026, 23:42 UTC

U.S. GDP Price Index Set for 3.7% Increase Amid Cautious Optimism and Inflation Concerns Ahead of Key Federal Reserve Policy Decisions.

25 jul 2026, 23:42 UTC

Traders Brace for PCE Price Index Release Amid Geopolitical Tensions and Inflation Concerns, Anticipating 0.4% Increase

25 jul 2026, 23:42 UTC

Core PCE Price Index MoM Release on July 30, 2026, Expected to Show Modest 0.1% Increase Amid Inflation Concerns and Market Sensitivity.

25 jul 2026, 23:42 UTC

U.S. Q2 2026 GDP Growth Rate Release Expected at 2.3% Amid Positive Economic Sentiment and Geopolitical Concerns

25 jul 2026, 23:32 UTC

S&P/Case-Shiller Home Price Index Set for July Release Amidst Cautious Market Sentiment and Inflation Concerns

25 jul 2026, 23:32 UTC

South Africa's upcoming balance of trade data on July 31, 2026, is under scrutiny as analysts anticipate continued deficits amid rising imports and geopolitical tensions.

25 jul 2026, 23:31 UTC

"Cryptocurrency Gains Amid Geopolitical Tensions; European Stocks Shift and Fed's Rate Decision Looms"

25 jul 2026, 23:31 UTC

Cryptocurrency gains amid European market reassessment and bond turmoil, as investors brace for the Fed's interest rate decision and Japan's fiscal policy shift.

25 jul 2026, 23:31 UTC

Bitcoin and Ethereum rise amid shifting European equity markets, Japan's fiscal policy changes, and looming Federal Reserve interest rate decision.

25 jul 2026, 23:31 UTC

Cryptocurrency prices rise as Bitcoin and Ethereum gain, while European equity markets face shifts and Japan's fiscal policy change looms ahead of the Federal Reserve's interest rate decision.

25 jul 2026, 23:24 UTC

Mexico's Q2 GDP Growth Rate Release on July 30 Sparks Cautious Optimism Amid Strong Services PMI Performance.

25 jul 2026, 23:24 UTC

Brazil's Unemployment Rate Expected to Remain Stable or Improve in June 2026 Amid Cautious Optimism and Economic Recovery Concerns

25 jul 2026, 23:13 UTC

Mexico's Q2 2026 GDP Growth Rate Release on July 30 Sparks Caution Amid Geopolitical Tensions and Trade Tariff Concerns.

25 jul 2026, 23:13 UTC

Japan's Industrial Production MoM data for June 2026 set to release on July 30, with a modest increase of 0.7% anticipated amid mixed economic sentiment and rising inflation concerns.

25 jul 2026, 23:13 UTC

Germany's Inflation Rate Release on July 30, 2026: Market Anticipates Continued Pressure Amid Mixed Economic Signals.

25 jul 2026, 23:13 UTC

Japan's Retail Sales Expected to Rise 2.8% YoY Amid Concerns Over Consumer Spending and Economic Recovery Challenges

25 jul 2026, 23:13 UTC

Germany's July Inflation Rate Expected to Rise 0.7% Amid Mixed Economic Sentiment and Rising Oil Prices

25 jul 2026, 23:03 UTC

Wholesale Inventories MoM Advance Data Set for Release Amid Mixed Economic Sentiment and Geopolitical Tensions, Forecasting 0.2% Increase.

25 jul 2026, 23:03 UTC

U.S. Goods Trade Balance Release Expected to Show $98 Billion Deficit Amid Tariff Concerns and Inflation Pressures

25 jul 2026, 23:03 UTC

U.S. Retail Inventories Ex Autos Data Release on July 28, Amid Weakening Consumer Spending and Inflation Concerns

25 jul 2026, 23:01 UTC

Avalanche continues to trade higher, reflecting strong performance since Friday's close. Earlier, it peaked over 8%, remaining above its 20-day moving average.

25 jul 2026, 22:51 UTC

Japan's June 2026 unemployment rate forecast at 2.5% amid rising inflation concerns and market volatility ahead of release on July 30, signaling mixed investor sentiment.

25 jul 2026, 22:42 UTC

Durable Goods Orders Report on July 27, 2026 Expected to Show Recovery Amidst Market Volatility and Geopolitical Tensions.

25 jul 2026, 22:42 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.9% in June Amid Cautious Optimism and External Economic Pressures

25 jul 2026, 22:42 UTC

Mortgage Rates Hit 6.69% Amid Rising Treasury Yields and Inflation Concerns, Influencing Real Estate Market Dynamics

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

141.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 141.78%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.